The involvement of this molecule on renal impairment is confirmed by the fact that PPARγ agonists can slow or even prevent the progression of various kidney injuries including diabetic nephropathy via multiple mechanisms involving activation of PPARγ in the kidney and other tissue. This evidence concerns the gene PPARG and diabetic kidney disease.